Cynata Therapeutics Limited (51S) AI Stock Analysis

0 Followers

Cynata Therapeutics Limited

(Frankfurt:51S)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Off-the-shelf cell therapy platformAn allogeneic, off-the-shelf platform can support standardized production and broader commercial distribution than individualized cell therapies. Cymerus™ provides a defined technology base across multiple immunomodulatory disease programs, creating potential for platform-level expansion if clinical development succeeds.

Negative Factors

Persistent operating lossesLarge recurring losses relative to revenue show that the current business has not yet reached operating scale or profitability. Continued negative earnings can consume capital, limit internally funded development, and make financial performance dependent on successful commercialization or additional external funding.

Cynata Therapeutics Limited (51S) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.77M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.4
Beta (1Y): -1.34
Revenue Growth: ―
EPS Growth: 14.11%
Country: Germany
Employees: 0
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Cynata Therapeutics Limited Business Overview & Revenue Model

Company Description

Headquartered in Cremorne, Australia, Cynata Therapeutics Limited, established in 2003 and formerly known as Eco Quest Limited until its 2013 rebranding, specializes in the development and commercialization of its proprietary Cymerus mesenchymal stem...

Cynata Therapeutics Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:51S against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AU:MSB	70Outperform	AUD 2.71B	-30.92	-10.06%	―	555.67%	49.08%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AU:TRP	50Neutral	AUD 6.92M	-1.24	-52.04%	―	32.22%	-26.53%
AU:OCC	44Neutral	AUD 162.07M	-10.94	-36.83%	―	51.07%	-47.63%
AU:1AI	40Underperform	AUD 16.22M	-5.14	-132.20%	―	―	-200.00%
AU:CMB	39Underperform	AUD 10.60M	-1.43	-247.44%	―	-4.24%	33.39%

* Healthcare Sector Average

Performance Comparison

DE:51S and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:51S	Cynata Therapeutics Limited	0.14	0.01	10.57%
AU:1AI	Living Cell Technologies Ltd.	0.01	0.00	0.00%
AU:MSB	Mesoblast Limited	1.96	-0.27	-11.94%
AU:OCC	Orthocell Ltd	0.57	-0.47	-44.71%
AU:TRP	Tissue Repair Ltd	0.11	-0.19	-63.33%
AU:CMB	Regeneus Ltd.	0.36	-0.15	-28.71%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Cynata Therapeutics Limited AI Stock Analysis